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Background: MicroRNAs (miRNAs) are short, non-coding RNA molecules that play critical roles in human malignancy.
However, the regulatory characteristics of miRNAs in triple-negative breast cancer, a phenotype of breast cancer that
does not express the genes for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor
2, are still poorly understood.
Methods: In this study, miRNA expression profiles of 24 triple-negative breast cancers and 14 adjacent normal
tissues were analyzed using deep sequencing technology. Expression levels of miRNA reads were normalized with
the quantile-quantile scaling method. Deregulated miRNAs in triple-negative breast cancer were identified from
the sequencing data using the Student’s t-test. Quantitative reverse transcription PCR validations were carried out
to examine miRNA expression levels. Potential target candidates of a miRNA were predicted using published target
prediction algorithms. Luciferase reporter assay experiments were performed to verify a putative miRNA-target
relationship. Validated molecular targets of the deregulated miRNAs were retrieved from curated databases and
their associations with cancer progression were discussed.
Results: A novel 25-miRNA expression signature was found to effectively distinguish triple-negative breast cancers
from surrounding normal tissues in a hierarchical clustering analysis. We documented the evidence of seven
polycistronic miRNA clusters preferentially harboring deregulated miRNAs in triple-negative breast cancer. Two of
these miRNA clusters (miR-143-145 at 5q32 and miR-497-195 at 17p13.1) were markedly down-regulated in
triple-negative breast cancer, while the other five miRNA clusters (miR-17-92 at 13q31.3, miR-183-182 at 7q32.2,
miR-200-429 at 1p36.33, miR-301b-130b at 22q11.21, and miR-532-502 at Xp11.23) were up-regulated in triple-
negative breast cancer. Moreover, miR-130b-5p from the miR-301b-130b cluster was shown to directly repress the
cyclin G2 (CCNG2) gene, a crucial cell cycle regulator, in triple-negative breast cancer cells. Luciferase reporter
assays showed that miR-130b-5p-mediated repression of CCNG2 was dependent on the sequence of the 3′-untranslated
region. The findings described in this study implicate a miR-130b-5p-CCNG2 axis that may be involved in the
malignant progression of triple-negative breast cancer.
Conclusions: Our work delivers a clear picture of the global miRNA regulatory characteristics in triple-negative
breast cancer and extends the current knowledge of microRNA regulatory network.
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Breast cancer is a heterogeneous disease that can be
classified into several histological forms in current clin-
ical practice. The molecular etiologies among different
types of breast cancers are largely different, making
the treatment of breast cancer difficult. Triple-negative
breast cancer, which is characterized by the lack of ex-
pression of the estrogen receptor (ER), the progesterone
receptor (PR), and the human epidermal growth factor
receptor 2 (HER2), is a type of breast cancer with
aggressive tumor behavior. Many targeted treatments,
including endocrine therapies and HER2-targeted medi-
cine, are not efficacious for triple-negative breast cancer
[1,2]. Although previous studies have shown that the
vast majority of triple-negative breast cancers display
basal-like gene expression features [3,4] the molecular
mechanisms driving tumor progression of triple-negative
breast cancer still remain unknown.
MicroRNAs (miRNAs) are short (~21mer) non-coding
RNA molecules that are important in gene expression
regulation [5,6]. The primary role of miRNAs appears to
be in the negative regulation of the expression of mes-
senger RNA (mRNA) transcripts. The functional strand
of a mature miRNA guides the RNA-induced silencing
complex to bind a target mRNA in the 3′-untranslated
region (3′-UTR), initiating translational repression, tar-
get mRNA cleavage, or mRNA deadenylation of the tar-
get gene. Emerging evidence has shown that aberrant
miRNA expression plays a critical role in the tumorigen-
esis of many human cancers [7-9]. Some miRNAs are
shown to possess oncogenic characteristics that promote
malignancy of human cancers [10], while some have
tumor-suppressing abilities to reduce the production of
oncogenic proteins [11,12].
The advent of deep sequencing technology allowed us
to explore the largely unknown territory of the miRNA
transcriptome in triple-negative breast cancer. Sequen-
cing reads of miRNA expression data from 24 triple-
negative breast cancers and 14 adjacent normal tissues
were analyzed for the presence of deregulated miRNAs
in this study. Differentially expressed miRNAs in triple-
negative breast cancer were determined by statistical
analyses of the sequencing data and were validated using
the quantitative reverse transcription PCR (RT-PCR)
method. We identified seven polycistronic miRNA clus-
ters in the human genome harboring 29 deregulated
miRNAs in triple-negative breast cancer. Furthermore,
our work extends the potential target network of miR-
NAs by showing that the cyclin G2 gene (CCNG2) is a
direct target of miR-130b-5p from the miR-301b-130b
cluster. Forced expression of miR-130b-5p was found to
significantly repress the endogenous expression levels of
CCNG2 in triple-negative breast cancer cells. The find-
ings described in this work may provide insights into themiRNA regulatory mechanisms underlying the tumori-
genicity of triple-negative breast cancer.
Results
A 25-miRNA signature discriminating triple-negative
breast cancer from adjacent normal tissue
Clinical information on the patients was recorded as
shown in Table 1. A total of 113,412,568 miRNA reads
were identified from 24 triple-negative breast cancers
and 14 adjacent normal tissues after sequence alignment
with the human miRNA reference, yielding a median
of 2,670,242 miRNA reads per sample from our data
(range: 393,305-7,906,634; Additional file 1). Setting a
threshold to filter out the miRNAs with extremely
low reads (mean expression <5 reads across 38 samples),
we identified 707 mature miRNAs. The reads from those
707 miRNAs constituted 99.97% of all miRNA reads in
our data for further analysis. The miRNA reads in each
sample were normalized using the quantile-quantile scal-
ing method on a log10-scale. Normalized expression data
from each of the 707 miRNAs was used as input to gener-
ate a PCA plot to visually assess the intrinsic variation in
the global miRNA profiles among the samples. The PCA
plot showed that the global miRNA portrait was able to
roughly separate the majority of triple-negative breast can-
cers from the adjacent normal tissues (Figure 1A).
Differentially expressed miRNAs between the triple-
negative breast cancer group (N = 24) and the adjacent
normal tissue group (N = 14) were identified using
Student’s t-test and the Holm step down procedure
for p-value adjustment. A list of the top 25 significantly
differentially expressed miRNAs (adjusted p <0.05) was
determined as shown in Table 2. Average-linkage hier-
archical clustering analysis was performed on the sam-
ples using the expression data from the 25 miRNAs
(Figure 1B). All triple-negative breast cancers and
adjacent normal tissues were distinctively divided into
two clusters without any misclassification. To examine
whether the 25-miRNA signature contained relevant
information in classification of triple-negative breast
cancers and normal breast tissues in PCA, each sample
was projected onto the principal components using the
expression data from the 25 miRNAs (Figure 1C). The
PCA plot revealed that the triple-negative breast can-
cers and the adjacent normal tissues were clearly sepa-
rated into two groups using the 25-miRNA signature.
Polycistronic miRNA clusters harboring differentially
expressed miRNAs in triple-negative breast cancer
The miRNAs residing closely in the same intron, exon,
or intergenic region of the human genome were shown
to have similar expression patterns in our data. A total
of seven miRNA clusters in the human genome were
found to be the genomic loci of deregulated miRNAs in
Table 1 Clinical information on 24 triple-negative breast cancer patients
Sample ID Age (years) Stage Gradea Tumor sizeb LYMc Recurrence statusd Recurrence-free time (years)
452_T 54 I 2 1 0 0 6.6
477_T 27 I 3 1 0 0 6.5
593_T 55 I 3 1 0 0 5.9
602_T 44 I 3 1 0 0 5.9
621_T 62 I 2 1 0 0 5.8
894_T 54 I 2 1 0 0 4.6
922_T 63 I 3 1 0 0 4.5
417_T 33 IIA 3 2 0 0 6.8
507_T 54 IIA 3 1 1 0 6.4
545_T 55 IIA 3 2 0 0 6.2
557_T 60 IIA 3 2 0 0 6.1
574_T 57 IIA 2 2 0 0 6.0
582_T 83 IIA 3 2 0 1 3.5
619_T 37 IIA 3 2 0 1 1.8
673_T 61 IIA 2 2 0 1 0.7
887_T 49 IIA 3 2 0 0 4.6
917_T 51 IIA 3 2 0 0 4.5
918_T 38 IIA 3 2 0 0 4.5
941_T 52 IIA 3 1 1 0 4.4
677_T 65 IIB 3 2 1 0 5.5
881_T 58 IIB 3 2 1 0 4.7
893_T 55 IIB 3 2 1 1 1.5
291_T 85 IIIA 3 3 1 1 1.2
357_T 57 IIIC 3 2 1 0 7.1
aGrade: 1/2/3, low/intermediate/high.
bTumor size: 1/2/3, <2 cm/2 cm-5 cm/>5 cm.
cLYM, lymph node metastasis: 0/1, negative/positive.
dRecurrence: 0/1, negative/positive.
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members, including miR-143-5p, miR-145-3p, and
miR-145-5p, in the miR-143-145 cluster located in the
intergenic region at 5q32 were all significantly down-
regulated (p <0.05; fold change 2.4-3.4). In addition,
miR-497-5p and miR-195-5p, in the miR-497-195 cluster
located in the intronic region of MIR497HG at 17p13.1,
were both significantly down-regulated (p <0.05; fold
change 3.0-3.3) in triple-negative breast cancer. On the
other hand, five other miRNA clusters were found to
comprise 24 up-regulated miRNAs in triple-negative
breast cancer. These overexpressed miRNAs include
four miRNAs (p <0.05; fold change 1.9-3.0) in the miR-
17-92 cluster, five miRNAs (p <0.05; fold change 2.5-
3.8) in the miR-183-182 cluster, four miRNAs (p <0.05;
fold change 1.7-3.1) in the miR-200b-429 cluster, three
miRNAs (p <0.05; fold change 2.2-3.6) in the miR-301b-
130b cluster, and eight miRNAs (p <0.05; fold change
2.0-2.6) in the miR-532-502 cluster.Quantitative RT-PCR validations of the deregulated
miRNAs
To confirm the results obtained from the sequencing
data, quantitative RT-PCR validations were carried out
to examine the expression levels of the miRNAs residing
in the miR-532-502 cluster, the miR-301b-130b cluster,
and the miR-497-195 cluster in 19 triple-negative breast
cancers and 4 adjacent normal tissues using the com-
parative CT method [13]. A conceptual diagram that
depicts the specific 5p/3p miRNA forms located at each
locus in the miR-532-502 cluster is shown in Figure 2A.
miR-532-5p (Figure 2B; mean fold change 2.4), miR-
188-3p (Figure 2C; mean fold change 2.5), miR-362-5p
(Figure 2D; mean fold change 4.0), miR-501-3p (Figure 2E;
mean fold change 5.3), miR-660-3p (Figure 2F; mean
fold change 2.2), and miR-502-5p (Figure 2G; mean fold
change 3.0) were all markedly up-regulated in the triple-
negative breast cancers compared to the normal breast
tissue controls.
Figure 1 A 25-miRNA expression signature discriminating between triple-negative breast cancers and adjacent normal tissues. (A) The
global miRNA expression portrait from each sample was investigated using principal component analysis. Each data point in the principal
component plot is composed of gene expression data of 707 mature miRNAs from a sample. Triple-negative breast cancers are shown in red
and adjacent normal tissues are shown in blue. (B) Hierarchical clustering analysis of triple-negative breast cancers (red) and adjacent normal
tissues (green) was performed using the 25 differentially expressed miRNAs. Each row represents the normalized gene expression data of a
miRNA and each column represents a tissue sample. The dendrogram depicts similarities in the gene expression profiles among the samples.
(C) Triple-negative breast cancers (red) and adjacent normal tissues (blue) are clearly separated into two groups in the principal component
analysis using the gene expression data of the 25 differentially expressed miRNAs.
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locus in the miR-301b-130b cluster. Quantitative RT-
PCR data confirmed that miR-301b-5p, miR-130b-5p,
and miR-130b-3p were all up-regulated in 19 triple-
negative breast cancer samples (Figure 3B-D, respectively).
Two 5p miRNA forms, miR497-5p and miR-195-5p,located at two different loci in the miR-497-195 cluster
are shown in Figure 3E. Compared with the normal
breast tissue controls, the expression levels of miR497-
5p were markedly down-regulated (Figure 3F; mean fold
change 0.3) in triple-negative breast cancers. Furthermore,
miR-195-5p in the same cluster was down-regulated
Table 2 Twenty-five differentially expressed miRNAs between triple-negative breast cancers and adjacent normal tissuesa
miRNA Raw p value Adjusted p value Triple-negative breast cancer Adjacent normal tissue
Mean Range Mean Range
Normalized Min Max Normalized Min Max
hsa-miR-215 3.21E-08 4.66E-06 32 0 86 321 80 928
hsa-miR-497-5p 2.43E-06 3.49E-04 1980 354 6215 6520 2335 18692
hsa-miR-204-5p 4.69E-06 6.71E-04 98 0 569 2518 37 14352
hsa-miR-425-5p 5.98E-06 8.49E-04 23266 7198 57542 9180 4551 16066
hsa-miR-96-5p 1.34E-05 1.89E-03 4568 898 12421 1545 494 3892
hsa-miR-1301 1.72E-05 2.40E-03 592 0 4777 43 0 188
hsa-miR-335-3p 2.89E-05 4.02E-03 1173 118 4234 5591 440 11145
hsa-miR-183-5p 5.13E-05 7.08E-03 6223 1305 24697 1928 602 5753
hsa-miR-24-2-3p 6.04E-05 8.27E-03 6782 2062 17902 3254 1553 5731
hsa-miR-130b-5p 7.64E-05 1.04E-02 3729 1413 10634 1352 159 2856
hsa-miR-92a-3p 9.93E-05 1.34E-02 182 0 1151 0 0 0
hsa-miR-320a-3p 1.15E-04 1.54E-02 11490 0 29381 2273 0 26275
hsa-miR-130b-3p 1.23E-04 1.64E-02 550 204 1683 246 110 579
hsa-miR-145-5p 1.47E-04 1.94E-02 256 9 603 877 202 2457
hsa-miR-126-3p 1.55E-04 2.03E-02 44031 16691 108893 134103 29907 285350
hsa-miR-139-5p 1.57E-04 2.04E-02 693 181 2537 6623 307 23210
hsa-let-7a-3p 1.59E-04 2.05E-02 175 0 428 41 0 326
hsa-miR-489-5p 1.59E-04 2.05E-02 8 0 63 118 0 483
hsa-miR-362-5p 1.69E-04 2.15E-02 2216 1186 5092 1006 297 2303
hsa-miR-429-5p 1.91E-04 2.40E-02 6416 1486 23455 2082 406 8716
hsa-miR-19b-3p 2.43E-04 3.04E-02 569 0 3214 0 0 0
hsa-miR-362-3p 2.56E-04 3.17E-02 1043 565 2168 448 43 845
hsa-miR-320a-5p 2.72E-04 3.34E-02 1354 0 17859 4369 0 15247
hsa-miR-337-5p 3.44E-04 4.19E-02 386 9 961 1309 334 4086
hsa-miR-143-5p 3.91E-04 4.73E-02 43060 3104 99397 102717 29650 36464
aNormalized miRNA reads from each sample were obtained after quantile-quantile scaling. The raw p-value of each miRNA was calculated using the log10-scaled
miRNA expression data after quantile-quantile scaling and was adjusted using the Holm step down procedure. Relative expression levels are shown.
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breast cancers in the quantitative RT-PCR validations.
miR-130b-5p directly silences endogenous CCNG2
expression levels in MDA-MB-231 cells
To understand how these deregulated miRNAs might
function in triple-negative breast cancer, we performed
target prediction of the miRNAs as described in the
Methods section. Among those putative target candi-
dates, five potential tumor suppressors, including CCNG2,
FOXP1, NRG1, LRIG1, and TNFSF10, were shown to have
a direct binding site with miR-130b-5p. We were particu-
larly interested in CCNG2, because it was a crucial regula-
tory gene in cell cycle control [14,15]. Previous studies
have functionally linked the decrease or complete loss of
CCNG2 in human cancer to uncontrolled cell prolifera-
tion [16,17]. We thus further characterized the regulatory
mechanism of miR-130b-5p in relation to CCNG2 in cells.A schematic diagram of the putative miR-130b-5p binding
site in the 3′-UTR of CCNG2 is shown in Figure 4A. Two
luciferase reporter constructs, Luc-CCNG2-UTR and Luc-
CCNG2-UTR-mt3, were made to test whether miR-130b-
5p might directly target CCNG2 in the putative binding
site. The possible binding sequences in the 3′-UTR of
CCNG2 were carried by the CCNG2 gene reporter, Luc-
CCNG2-UTR. The other luciferase reporter construct,
Luc-CCNG2-UTR-mt3, was made to carry three mutated
nucleotides at the putative binding site to disrupt binding
of miR-130b-5p to CCNG2. The luciferase reporter assays
revealed that miR-130b-5p significantly reduced the lucif-
erase activity of the wild-type CCNG2 gene reporter, but
not that of the site-directed mutant (Figure 4B), suggesting
that miR-130b-5p had a suppressive effect at the predicted
binding site in the 3′-UTR of CCNG2.
Next, we examined whether miR-130b-5p might repress
endogenous CCNG2 expression in triple-negative breast
Table 3 Polycistronic miRNA clusters harboring deregulated miRNAs between triple-negative breast cancers and adjacent
normal tissuesa
miRNA p value Triple-negative breast cancer Adjacent normal tissue Fold changeb in expression
Mean Range Mean Range
Normalized Min Max Normalized Min Max
Down-regulated miRNAs in triple-negative breast cancer
miR-143-145 cluster (Chromosome 5 q32, intergenic)
hsa-miR-143-5p 3.91E-04 43060 3104 99397 102717 29650 364644 2.4
hsa-miR-145-3p 7.36E-03 128335 8310 287564 404278 43410 1212945 3.2
hsa-miR-145-5p 1.47E-04 256 9 603 877 202 2457 3.4
miR-497-195 cluster (Chromosome 17 p13.1, MIR497HG intron 1)
hsa-miR-497-5p 2.43E-06 1980 354 6215 6520 2335 18692 3.3
hsa-miR-195-5p 3.18E-03 239 52 504 721 128 2492 3.0
Up-regulated miRNAs in triple-negative breast cancer
miR-17-92 cluster (Chromosome 13 q31.3, C13orf25 intron 3)
has-miR-17-3p 2.66E-02 40467 7676 137962 21080 5047 67282 1.9
has-miR-18a-3p 1.43E-02 6362 904 26300 2141 0 11488 3.0
has-miR-19b-3p 9.93E-05 569 0 3214 0 0 0 N/A
has-miR-92a-3p 2.43E-04 182 0 1151 0 0 0 N/A
miR-183-182 cluster (Chromosome 7 q32.2, intergenic)
hsa-miR-183-3p 5.42E-03 160 29 431 63 0 155 2.5
hsa-miR-183-5p 5.13E-05 6223 1305 24697 1928 602 5753 3.2
hsa-miR-96-3p 2.70E-03 65 0 163 26 0 106 2.5
hsa-miR-96-5p 1.34E-05 4568 898 12421 1545 494 3892 3.0
hsa-miR-182-5p 4.76E-03 13189 2441 40871 3501 7 7623 3.8
miR-200b-429 cluster (Chromosome 1 p36.33, intergenic)
hsa-miR-200b-3p 2.65E-02 694 156 2348 398 35 1061 1.7
hsa-miR-200a-3p 2.46E-02 77 0 362 40 0 296 1.9
hsa-miR-200a-5p 1.25E-03 46665 1800 160398 15886 2412 46254 2.9
hsa-miR-429-5p 1.91E-04 6416 1486 23455 2082 406 8716 3.1
miR-301b-130b cluster (Chromosome 22 q11.21, PPIL2 exon 2)
hsa-miR-301b-5p 1.41E-03 323 103 1483 89 0 244 3.6
hsa-miR-130b-3p 1.23E-04 550 204 1683 246 110 579 2.2
hsa-miR-130b-5p 7.64E-05 3729 1413 10634 1352 159 2856 2.8
miR-532-502 cluster (Chromosome X p11.23, CLCN5 intron 3)
hsa-miR-532-5p 1.58E-02 514 125 2731 253 31 990 2.0
hsa-miR-188-3p 2.72E-02 1159 509 5061 520 0 1258 2.2
hsa-miR-362-3p 2.56E-04 1043 565 2168 448 43 845 2.3
hsa-miR-362-5p 1.69E-04 2216 1186 5092 1006 297 2303 2.2
hsa-miR-501-3p 2.13E-02 335 125 1439 143 0 258 2.3
hsa-miR-660-3p 3.00E-02 11371 5546 23930 4438 0 9196 2.6
hsa-miR-502-3p 1.01E-02 144 60 339 68 0 129 2.1
hsa-miR-502-5p 2.55E-02 354 98 717 174 0 351 2.0
aNormalized miRNA reads from each sample were obtained after quantile-quantile scaling. The p-value is calculated using the log10-scaled miRNA expression data
without the Holm adjustment. Relative expression levels are shown.
bFold change was obtained by comparing the mean normalized miRNA expression reads between the triple-negative breast cancers and adjacent normal tissues.
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Figure 2 RT-PCR validations of six differentially expressed miRNAs in the miR-532-502 cluster in triple-negative breast cancer. (A) A
conceptual diagram illustrates the genomic loci harboring the 5p miRNA forms (brown) and 3p forms (orange) in the miR-532-502 cluster. The
names of specific miRNA forms are provided under each locus. Relative expression levels of (B) miR-532-5p, (C) miR-188-3p, (D) miR-362-5p, (E)
miR-501-3p, (F) miR-660-3p, and (G) miR-502-5p in triple-negative breast cancer tissues (n = 19) and adjacent normal tissues (n = 4) are shown.
In each panel, paired tissue samples from the same patient are indicated with the same digits in the sample ID. The miRNA expression level in
557-N served as the calibrator control. All six miRNAs examined in the miR-532-502 cluster were markedly up-regulated in triple-negative breast
cancer. Each bar represents the mean of triplicate measurements ± the SD.
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out in MDA-MB-231 cells using plasmid DNA trans-
fection of a lentiviral vector containing the precursor
sequence of miR-130b-5p. Quantitative RT-PCR data con-
firmed that the endogenous expression levels of CCNG2
were significantly repressed in MDA-MB-231 cells after
overexpression of miR-130b-5p (Figure 4C). Compared
with negative controls, a marked reduction (>50%) in
CCNG2 expression level was observed in the miR-130b-
5p-overexpressed MDA-MB-231cells.
The functional relevance of miR-130b-5p in cell cycle
regulation with triple-negative breast cancer cells was
analyzed in this study. After overexpression of miR-
130b-5p, MDA-MB-231 cells showed significant alter-
ations (p <0.05) in cell cycle profile (Additional file 2). Asignificant decrease in G1 phase and increases in S and
G2/M phases were observed with the miR-130b-5p-over-
expressed MDA-MB-231cells in the cell cycle analysis.
These results strongly support that miR-130b-5p plays a
role in cell cycle progression through suppression of
CCNG2 expression in triple-negative breast cancer.
We then investigated an association between miR-
130b-5p expression and malignancy of triple-negative
breast cancer from the sequencing data in our cohort.
Sequencing data of miR-130b-5p expression were shown
to be significantly associated with tumor progression in
both early-stage triple-negative breast cancers (p = 0.002;
n = 7) and advanced stage triple-negative breast cancers
(p <0.001; n = 17) in Figure 4D. The expression levels of
CCNG2 in our cohort of 38 samples were also measured
Figure 3 RT-PCR validations of the differentially expressed miRNAs in the miR-301b-130b cluster and the miR-497-195 cluster. (A) A
conceptual diagram illustrates the genomic loci harboring the 5p miRNA forms (brown) and 3p forms (orange) in the miR-301b-130b cluster.
Relative expression levels of (B) miR-301b-5p, (C) miR-130b-5p, and (D) miR-130b-3p in triple-negative breast cancer tissues (n = 19) and adjacent
normal tissues (n = 4) are shown. All three miRNAs in the miR-301b-130b cluster were markedly up-regulated in triple-negative breast cancer. (E)
A conceptual diagram illustrates the genomic loci harboring the 5p miRNA forms (brown) in the miR-497-195 cluster. Relative expression levels of
(F) miR-497-5p and (G) miR-195-5p in 23 samples are shown. Both miRNAs in the miR-497-195 cluster were down-regulated in triple-negative
breast cancer. Each bar represents the mean of triplicate measurements ± the SD.
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ation between high miR-130b-5p expression (p <0.001;
fold change 2.8) and low CCNG2 expression (p <0.001;
fold change 0.5) was observed in our triple-negative breast
cancer samples as compared with normal breast tissue
controls (Additional file 3A and B).
Discussion
Sequencing data of miRNA expression reads from 24
triple-negative breast cancers and 14 adjacent normal
tissues were analyzed in this study. Deregulated miRNAs
were identified from the statistical analyses and a panel
of the top 25 deregulated miRNAs was found to be an
effective discriminator between triple-negative breastcancers and adjacent normal tissues. Deep sequencing
technology allowed us to generate a comprehensive
insight into the cellular transcriptome in triple-negative
breast cancer that led to the identification of many more
deregulated miRNAs not described in previous studies
[18,19]. For example, aberrant expression from the miR-
532-502 cluster in triple-negative breast cancer was first
documented in this study. Interestingly, the expression
level of the tumor suppressor gene RUNX3 was found to
be inversely correlated with that of miR-532-5p from the
miR-532-502 cluster in primary melanomas [20].
A number of the validated target genes of the deregu-
lated miRNAs in our findings were shown to be involved
in human cancer signaling cascades (Additional file 4).
Figure 4 miR-130b-5p directly silences CCNG2 expression in triple-negative breast cancer cells. (A) Schematic diagram of the putative
miR-130b-5p binding site in the 3′-UTR of CCNG2. The possible binding sequence of miR-130b-5p with the 3′-UTR of CCNG2 is shown in red. (B)
Luciferase assays of CCNG2 in miR-130b-5p-overexpressed HEK-293 T cells. Two luciferase reporter constructs, Luc-CCNG2-UTR and Luc-CCNG2-
UTR-mt3, were made to test whether miR-130b-5p directly targets the putative binding site in the 3′-UTR of CCNG2. The mutated nucleotides are
indicated in red. Compared with the negative control, overexpression of miR-130b-5p was shown to significantly inhibit luciferase reporter activity
with Luc-CCNG2-UTR, but not with Luc-CCNG2-UTR-mt3. Each bar represents the mean of triplicate measurements ± the SD; *p <0.05. (C) Endogenous
expression analysis of CCNG2 in MDA-MB-231 cells transfected with lentiviral vectors containing miR-130b-5p precursor sequences. The endogenous
expression levels of CCNG2 were significantly repressed after the forced expression of miR-130b-5p in MDA-MB-231 cells. (D) Comparisons of
miR-130b-5p expression in normal breast tissues (n = 14), early-stage triple-negative breast cancers (n = 7), and advanced-stage triple-negative breast
cancers (n = 17). MiRNA expression reads were normalized and analyzed in log10 scale. miR-130b-5p expression was significantly associated with both
early-stage and advanced-stage triple-negative breast cancers.
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145-5p in the miR-143-145 cluster were down-regulated
in triple-negative breast cancer. Down-regulation of these
two miRNAs was previously described in lung cancer,
colon cancer, and bladder cancer [21-23]. The proto-
oncogene c-Myc was a direct target for miR-145-5p, and
introduction of miR-145-5p repressed c-Myc expression
and tumor growth both in vitro and in vivo [11]. The
insulin receptor substrate-1 (IRS-1), previously known
as a major docking protein for both the type 1 insulin-like growth factor receptor and the insulin receptor
in cancer cell growth and proliferation signaling, was
also a validated target of miR-145-5p [24]. In addition,
Sachdeva et al. reported that cell invasion ability was
significantly inhibited by miR-145-5p, in part due to the
silencing of the metastasis geneMUC1 [25].
Deregulation of the miR-497-195 cluster has been
previously addressed in breast cancer. Li et al. described
that miR-497-5p and miR-195-5p in this cluster were
both down-regulated in human breast cancer tissues and
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determine whether the deregulation of these two miRNAs
observed in breast cancer cell lines was also observed in
triple-negative breast cancer tissues. Our results provide
evidence showing in vivo that both miR-497-5p and miR-
195-5p are down-regulated in triple-negative breast cancer
tissues. Furthermore, the methylation state of CpG islands
in the promoter region upstream of the miR497-195 clus-
ter was responsible for the down-regulation of those two
miRNAs in breast cancer, and direct targets of miR-195-
5p included CCND1 and RAF1 [26]. Moreover, intro-
duction of miR-195-5p was shown to inhibit cancer cell
colony formation in vitro [26] and tumor development
in nude mice [27], suggesting that ectopic expression of
miR-195-5p may be involved in the tumorigenesis of
breast cancer.
We were able to identify CCNG2 as a direct target of
miR-130b-5p in triple-negative breast cancer. Luciferase
reporter assays revealed that miR-130b-5p-mediated re-
pression of CCNG2 is dependent on the sequence of the
3′-UTR. CCNG2 is known as a negative regulator of cell
cycle progression. Previous microarray analyses have
shown that elevated CCNG2 expression induces cell cycle
arrest during responses to various types of growth inhibi-
tory effects, such as hypoxia, oxidative stress, and heat
shock [17,28,29]. The CCNG2 protein directly interacts
with the catalytic subunit of protein phosphatase 2A to
form active complexes that inhibit cell cycle progression
[15]. Increasingly, the evidence suggests that CCNG2 is
crucially involved in human cancer signaling pathways
[30-32]. For example, CCNG2 was a primary target gene
of estrogen-occupied estrogen receptor and that its ex-
pression was rapidly down-regulated by estrogens in
MCF-7 breast cancer cells [31]. Moreover, CCNG2 pro-
moter activity was found to be regulated by Nodal sig-
naling in ovarian cancer cells and silencing of CCNG2
expression significantly increased cell proliferation [32].
Gene expression levels of CCNG2 between triple-
negative breast cancers and normal breast tissues were
further investigated using a published microarray dataset
[GEO:GSE53752]. The gene expression levels of CCNG2
in triple-negative breast cancers (n = 51) were significantly
lower (p <0.001; fold change 1.9) than those in normal
breast tissues (n = 25) in the microarray data (Additional
file 5). Of added interest, recently CCNG2 was found to
be an important prognostic factor for triple-negative
breast cancer patients. In an analysis of a cohort of 250
primary triple-negative breast cancer samples from
eight clinically annotated gene expression datasets, triple-
negative breast cancer patients with low expression levels
of SHARP1 and CCNG2 had a significantly higher prob-
ability of developing metastases and of reduced survival
[33]. It is thus important that we identified CCNG2 as a
direct target of miR-130b-5p. The ability of miR-130b-5pto repress CCNG2 expression may enhance malignancy
by accelerating cell cycle transition in triple-negative
tumor cells.Conclusions
Our work clearly depicts the global miRNA regulatory
characteristics in triple-negative breast cancer. The 25-
miRNA signature determined in this study may be used
as a functional tool to distinguish triple-negative breast
cancer tissues from normal breast tissues. Seven polycis-
tronic miRNA clusters preferentially harboring deregu-
lated miRNAs were identified in triple-negative breast
cancer. Moreover, we extended the current knowledge of
microRNA regulatory network by showing that miR-
130b-5p in the miR-301b-130b cluster directly silences
CCNG2 in triple-negative breast cancer. It would be inter-
esting to test whether this novel regulatory mechanism of
miR-130b-5p and its CCNG2 target in triple-negative
breast cancer may be involved in other malignancies as
well. Our findings not only provide insight into the
miRNA regulatory mechanisms in triple negative breast
cancer, but also shed light on the identification of poten-
tial therapeutic targets for this disease.Methods
Breast cancer and normal tissue samples
Twenty-four triple-negative breast cancer samples and 14
adjacent normal tissue samples were collected from breast
cancer patients during surgeries at National Taiwan
University Hospital (NTUH, Taipei, Taiwan). All triple-
negative breast cancer samples were invasive ductal car-
cinomas and were negative in immunohistochemical
analyses of ER, PR, and HER2. AJCC/UICC TNM
staging system was used for tumor classification. Treat-
ment of each patient followed the National Comprehen-
sive Cancer Network (http://www.nccn.org/) guidelines.
All samples were neoadjuvant-free and were collected be-
fore systemic chemotherapy treatments. Written informed
consent was obtained from each patient who participated
in this study. All human tissues used in this study were ap-
proved by the institutional review board at NTUH.Small RNA library preparation
Total RNA was extracted from each sample for the
preparation of a small RNA library. The small RNA li-
brary was constructed from total RNA using the SOLiD
Total RNA-Seq Kit (Applied Biosystems, Foster City,
CA, USA). Integrity of each small RNA library was ex-
amined using an RNA 6000 Nano Chip (Agilent, Santa
Clara, CA, USA), a Small RNA Chip (Agilent), and the
Bioanalyzer (Agilent) according to the manufacturer’s
instructions.
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Upon completion of PCR amplification, the small RNA
libraries were purified using the SOLiD Library Micro
Column Purification Kit (Applied Biosystems) and hy-
bridized to the template beads using the SOLiD EZ bead
system (Applied Biosystems). The template beads were
amplified and deposited onto a tray for small RNA
ligation sequencing by the SOLiD 4 System (Applied
Biosystems). The sequencing data were uploaded to the
Gene Expression Omnibus (GEO) with an accession num-
ber of GSE40049.
Sequence alignment of miRNA reads
All reads obtained from ligation sequencing were first
screened to filter out the reads containing ribosomal
RNA, transfer RNA, and adaptor sequences. The remaining
reads were then aligned to the human miRNA reference
(miRBase v17.0) and the human genome reference
(RefSeq Hg19) using the Small RNA Analysis Tool (Ap-
plied Biosystems). In the sequence alignment, only one
mismatch was allowed for the first 16 bases of a miRNA
read. The maximum number of permitted mismatches
of a miRNA read was set at 4. Those reads that were not
uniquely mapped to the miRBase reference were disre-
garded to eliminate ambiguous alignments.
Statistical analyses
The quantile-quantile scaling method [34] was performed
for the normalization of miRNA expression reads in log10-
scale. All miRNA expression reads in each dataset were
linearly scaled to fit into a miRNA expression reference
made of the mean expression value of each miRNA from
38 samples. Principal component analysis (PCA) was per-
formed to analyze the miRNA expression profiles between
triple-negative breast cancers and adjacent normal tissues
with the Partek Genomics Suite (Partek Incorporated, St.
Louis, MO, USA). Significant differences in expression of
miRNAs from the triple-negative breast cancers and adja-
cent normal tissues were identified using two-tailed Stu-
dent’s t-tests. The Holm step down procedure was used to
counteract multiple comparisons. A p-value of <0.05 was
considered significant. The miRNAs with a fold change >2
and mean expression difference >100 reads between the
two groups were investigated in the hierarchical clustering
analysis using Genesis software (version 1.7.5).
Quantitative RT-PCR validation of miRNA expression
Differentially expressed miRNAs identified from our se-
quencing data were validated using quantitative RT-PCR
in 19 triple-negative breast cancer samples and 4 adjacent
normal tissue samples. Total RNA was extracted from
each sample and then reverse transcribed into miRNA-
specific cDNA following the standard protocol of the
TaqMan MicroRNA Reverse Transcription Kit (AppliedBiosystems). Relative quantification of miRNA expres-
sion in each sample was obtained using the comparative
threshold (CT) method [13]. Expression of U6 small
nuclear RNA was used as the endogenous control.
Putative target prediction
Potential mRNA target genes of a miRNA were searched
using the miRanda [35] and Diana [36] target prediction
algorithms. Putative target candidates having complemen-
tary base-pairing matches in the 3′-UTR for the indicated
miRNA seed region were obtained. Biological functions
associated with the target genes were investigated using
Ingenuity Pathway Analysis software (Ingenuity Systems,
Redwood City, CA, USA).
Experimentally validated miRNA target genes
Experimentally validated miRNA target genes were re-
trieved from TarBase [37] and miRecords [38] using the
miRSystem search engine [39]. The molecular pathways
encompassing the validated target genes were investi-
gated using Ingenuity Pathway Analysis software.
Cell lines
MDA-MB-231 and HEK-293 T were obtained from Biore-
source Collection and Research Center (Taiwan). The cell
lines were tested and authenticated by Genelabs Life
Science (Taiwan) using STR-PCR profiling.
Vectors
miR-130b-5p was cloned into a lentiviral vector PreMiR-
130b (System Biosciences, Mountain View, CA, USA)
that was used to overexpress the miRNA in MDA-MB-
231 cells. Expression of miR-130b-5p was verified and
quantified using KAPA PROBE Fast qPCR Master Mix
(Kapa Biosystems, Boston, MA, USA), and the LightCycler
480 System (Roche, Basel, Switzerland).
A CCNG2 luciferase reporter construct was made by
introducing the CCNG2 3′-UTR carrying a predicted
miR-130b-5p binding site (5′-CCTTGGAGATACTGA
AAGAGA-3′) into the pmirGLO control vector (Promega,
Madison, WI, USA). Site-directed mutagenesis of the puta-
tive miR-130b-5p binding site was made using a facile PCR
procedure [40]. All PCR products were verified by DNA
sequencing before use.
Luciferase assay
Luciferase assays were performed with HEK-293 T cells
using the Dual-Glo® Luciferase Assay System (Promega).
Cells were transfected with PreMiR-130b lentiviral vec-
tors using TransIT®-2020 transfection reagent (Mirus
Bio, Madison, WI, USA). Forty-eight hours after trans-
fection, the cells were then harvested and lysed for the
luciferase assay. Renilla luciferase signals were used for
normalization according to the manufacturer’s protocol.
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3×104 cells of MDA-MB-231 cells were seeded in a 24-
well plate. miR-130b-5p or empty vector (control) were
overexpressed in the MDA-MB-231 cells. Cell synchro-
nization was performed using double thymidine block.
2 mM of thymidine was added into cells and cells were in-
cubated at 37°C for 16 hours. To remove thymidine, cells
were washed with PBS and incubated with fresh media at
37°C for 8 hours. 2 mM of thymidine was added into cells
and cells were incubated at 37°C for 16 hours. To release
the cells from thymidine block, cells were washed with
PBS and incubated with fresh media and collected after
14 hours. The cells were harvested by trypsinization and
washed twice with cold PBS. The cells were fixed by 0.5 mL
of cold 95% ethanol and were kept at -20°C overnight. The
ethanol was removed and cells were washed twice with
PBS. The cells were resuspended in 500 μL of PI solution
(10 μg/mL of propidium iodide, 0.2 mg/mL of RNaseA
and 0.1% Triton X-100). Cell cycle profile was analyzed
by fluorescence-activated cell sorter (FACS) analysis.
Gene expression microarray experiments
Gene expression data of CCNG2 in our cohort of 38
samples (14 normal breast tissues and 24 triple-negative
breast cancer samples) were analyzed using Agilent Human
1A (version 2) microarray platform. Microarray expe-
riments were performed following the manufacturer’s
instructions. Microarray data were normalized using
Quantile normalization before statistical analyses.
Online supporting information
The sequencing data were uploaded to the Gene Ex-
pression Omnibus (GEO) with an accession number of
GSE40049.
Additional files
Additional file 1: Raw miRNA reads from triple-negative breast
cancers (N = 24) and adjacent normal tissues (N = 14) obtained using
the high-throughput sequencer.
Additional file 2: Cell cycle analysis showed significant alterations
in cell cycle profile in MDA_MB-231 cells after miR-130b-5p
overexpression. MDA-MB-231 cells were transfected with empty
vectors (control) or vectors containing miR-130b-5p precursor sequence.
Compared with vector controls, there was a significant decrease with the
cell population in G1 phase along with increases in S and G2/M phases
in the miR-130b-5p-overexpressed MDA_MB-231 cells. The data were
analyzed using paired t-test. *p <0.05. Bars, ±SD.
Additional file 3: Expression levels of miR-130b-5p and CCNG2
were inversely regulated between normal breast tissues (n = 14)
and triple-negative breast cancers (n = 24) in our cohort of 38
samples. (A) Normalized deep-sequencing reads of miR-130b-5p in
triple-negative breast cancers and normal breast tissue controls are
shown in the box plots. miR-130b-5p expression was significantly
(p <0.001) up-regulated in triple-negative breast cancers. The p value was
calculated with the normalized log10-scaled miRNA reads using the
parametric t-test. (B) Agilent microarray data of CCNG2 expression in
triple-negative breast cancers and normal breast tissue controls in ourcohort are shown in the box plots. Microarray data were normalized
using quantile normalization before the statistical analyses. CCNG2 was
significantly (p <0.001) down-regulated in triple-negative breast cancers.
Fold change was calculated using the mean expression data from the
two groups. The p value was obtained using the parametric t-test.
Additional file 4: Experimentally validated miRNA-target gene
relationships of the deregulated miRNAs in triple-negative breast
cancer. The associations between miRNAs and human cancer were
retrieved from curated databases.
Additional file 5: Comparison of CCNG2 expression levels between
normal breast tissues (n = 25) and triple-negative breast cancers
(n = 51) from a published microarray dataset [GEO:GSE33926]. The
microarray data were obtained using the Agilent Human 1A (version 2)
platform. Quantile normalization was performed on the microarray data
before the parametric t-test analysis. The p-value was adjusted using
Bonferroni correction for multiple comparisons. The microarray data
revealed that, compared with normal breast tissues, CCNG2 was significantly
down-regulated in triple-negative breast cancers.
Abbreviations
miRNA: MicroRNA; CCNG2: Cyclin G2; ER: Estrogen receptor; PR: Progesterone
receptor; HER2: Human epidermal growth factor receptor 2;
mRNA: messenger RNA; UTR: Untranslated region; RT-PCR: Reverse
transcription PCR; NTUH: National Taiwan University Hospital;
IHC: Immunohistochemical; GEO: Gene Expression Omnibus; PCA: Principal
component analysis; SD: Standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YYC and WHK carried out the miRNA transcriptome study, performed
bioinformatics analyses, and drafted the manuscript. JHH and CYL
participated in the miRNA sequencing alignment. YHL, WCL, and CYS
performed RT-PCR validation and luciferase assay experiments. CSH, FJH, LCL,
and MHT participated in the design of the study and high-throughput
sequencing data acquisition. KJC and EYC provided intellectual criticisms and
gave final approval to the manuscript to be published. All authors read and
approved the final manuscript.
Authors’ information
WHK and CSH are breast cancer surgeons at National Taiwan University
Hospital. LCL is a professor of Physiology at National Taiwan University.
MHT is a professor of Biotechnology at National Taiwan University. KJC is a
professor of Breast Surgery at National Taiwan University. EYC is a professor
of Biomedical Electronics and Bioinformatics at National Taiwan University.
Acknowledgements
This study was supported by grants from the Department of Health,
Taiwan (DOH101-TDC-111-001) and the National Science Council, Taiwan
(NSC97-2314-B-002-154-MY3). The sequencing data analyses were supported
by the Center of Biotechnology at National Taiwan University. We thank
Genelabs Life Science (Taiwan) for performing STR-profiling authentication of
the cell lines used in this study.
Author details
1Department of Electrical Engineering, Graduate Institute of Biomedical
Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.
2Department of Surgery, College of Medicine, National Taiwan University,
Taipei, Taiwan. 3Bioinformatics and Biostatistics Core, NTU Center of Genomic
Medicine, Taipei, Taiwan. 4Institute of Biotechnology, College of Bio-resources
and Agriculture, National Taiwan University, Taipei, Taiwan. 5Department of
Obstetrics and Gynecology, College of Medicine, National Taiwan University,
Taipei, Taiwan. 6Department of Physiology, College of Medicine, National
Taiwan University, Taipei, Taiwan. 7Department of Surgery, Cheng Ching
General Hospital, Taichung, Taiwan.
Received: 16 June 2014 Accepted: 21 January 2015
Chang et al. Molecular Cancer  (2015) 14:36 Page 13 of 13References
1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J
Med. 2010;363:1938–48.
2. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic
options. Lancet Oncol. 2007;8:235–44.
3. Van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene
expression profiling predicts clinical outcome of breast cancer. Nature.
2002;415:530–6.
4. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H,
et al. Gene expression profiling and histopathological characterization of
triple-negative/basal-like breast carcinomas. Breast Cancer Res: BCR.
2007;9:R65.
5. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA
biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.
6. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity:
microRNA biogenesis pathways and their regulation. Nat Cell Biol.
2009;11:228–34.
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A
microRNA expression signature of human solid tumors defines cancer gene
targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.
8. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al.
MicroRNA gene expression deregulation in human breast cancer. Cancer
Res. 2005;65:7065–70.
9. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S,
et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in
human lung cancers and enhances cell proliferation. Cancer Res.
2005;65:9628–32.
10. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth.
Oncogene. 2007;26:2799–803.
11. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses
c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad
Sci U S A. 2009;106:3207–12.
12. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new
tale. Cancer Res. 2006;66:7390–4.
13. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C
(T) method. Nat Protoc. 2008;3:1101–8.
14. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, et al.
Cyclin G2 is up-regulated during growth inhibition and B cell antigen
receptor-mediated cell cycle arrest. J Biol Chem. 1997;272:12650–61.
15. Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, et al.
Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory
B’ subunits in active complexes and induces nuclear aberrations and a G1/S
phase cell cycle arrest. J Biol Chem. 2002;277:27449–67.
16. Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, et al. Decreased
expression of cyclin G2 is significantly linked to the malignant
transformation of papillary carcinoma of the thyroid. Anticancer Res.
2003;23:2335–8.
17. Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in
human oral cancer. Cancer Res. 2004;64:8980–6.
18. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA,
Stathopoulos EN. MicroRNA expression analysis in triple-negative
(ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011;10:507–17.
19. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, et al.
Integrated microRNA and mRNA signatures associated with survival in triple
negative breast cancer. PLoS One. 2013;8:e55910.
20. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS. Regulation of RUNX3
tumor suppressor gene expression in cutaneous melanoma. Clinical Cancer
Res. 2009;15:2988–94.
21. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al.
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 2006;9:189–98.
22. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M,
et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is
related to clinicopathologic features of colorectal cancer. Oncology.
2007;72:397–402.
23. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD,
et al. miR-145 induces caspase-dependent and -independent cell death in
urothelial cancer cell lines with targeting of an expression signature present
in Ta bladder tumors. Oncogene. 2010;29:1073–84.24. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, de Angelis T, Baserga R. Micro
RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of
colon cancer cells. J Biol Chem. 2007;282:32582–90.
25. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis
by directly targeting mucin 1. Cancer Res. 2010;70:378–87.
26. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clinical Cancer Res.
2011;17:1722–30.
27. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses
tumorigenicity and regulates G1/S transition of human hepatocellular
carcinoma cells. Hepatology. 2009;50:113–21.
28. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M, et al.
Oral cancer in vivo gene expression profiling assisted by laser capture
microdissection and microarray analysis. Oncogene. 2001;20:6196–204.
29. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS.
Profiling of estrogen up- and down-regulated gene expression in human
breast cancer cells: insights into gene networks and pathways underlying
estrogenic control of proliferation and cell phenotype. Endocrinology.
2003;144:4562–74.
30. Ahmed S, Al-Saigh S, Matthews J. FOXA1 is essential for aryl hydrocarbon
receptor-dependent regulation of cyclin G2. Molecular Cancer Res.
2012;10:636–48.
31. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS.
Estrogen-occupied estrogen receptor represses cyclin G2 gene expression
and recruits a repressor complex at the cyclin G2 promoter. J Biol Chem.
2006;281:16272–8.
32. Fu G, Peng C. Nodal enhances the activity of FoxO3a and its synergistic
interaction with Smads to regulate cyclin G2 transcription in ovarian cancer
cells. Oncogene. 2011;30:3953–66.
33. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, et al.
SHARP1 suppresses breast cancer metastasis by promoting degradation of
hypoxia-inducible factors. Nature. 2012;487:380–4.
34. Schulte JH, Marschall T, Martin M, Rosenstiel P, Mestdagh P, Schlierf S, et al.
Deep sequencing reveals differential expression of microRNAs in favorable
versus unfavorable neuroblastoma. Nucleic Acids Res. 2010;38:5919–28.
35. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org
resource: targets and expression. Nucleic Acids Res. 2008;36:D149–53.
36. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T,
Reczko M, et al. DIANA-microT web server v5.0: service integration into
miRNA functional analysis workflows. Nucleic Acids Res. 2013;41:W169–73.
37. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M,
et al. TarBase 6.0: capturing the exponential growth of miRNA targets with
experimental support. Nucleic Acids Res. 2012;40:D222–9.
38. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource
for microRNA-target interactions. Nucleic Acids Res. 2009;37:D105–10.
39. Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, et al. miRSystem: an
integrated system for characterizing enriched functions and pathways of
microRNA targets. PLoS One. 2012;7:e42390.
40. Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC. Site-directed
mutagenesis of double-stranded DNA by the polymerase chain reaction.
Gene. 1994;151:119–23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
